6505--Ustekinumab Pens/Syringes or Biosimilar
ID: 36E79726R0006Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/f77b74fb4c5c44bb9c4a04cd84d391d3/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.

    Point(s) of Contact
    Christopher CarthronContract Specialist
    (708) 786-4980
    Christopher.Carthron@va.gov
    Files
    Title
    Posted
    36E79726R0006_1.docx
    The VA National Acquisition Center plans to issue RFP 36E79726R0006 for an unrestricted procurement of Ustekinumab Pen/Syringes or Biosimilar. This contract will supply the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. A single contract will be awarded for one year with four optional one-year periods, distributing items via VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique NDC numbers and labels. The solicitation is expected around January 12, 2026, closing tentatively on January 27, 2026, with NAICS code 325412. All documents will be available on sam.gov. Biosimilar products must be FDA-licensed and listed in the FDA Purple Book. Offerors must provide both syringe and vial versions for any strength/line item where both are commercially available, at the same price. Estimated annual usage includes 2,917 units of 5MG/ML, 9,608 units of 45MG/0.5ML, and 45,763 units of 90MG/ML. Chris Carthron is the point of contact.
    Lifecycle
    Title
    Type
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking information from domestic pharmaceutical manufacturers through a Request for Information (RFI) designated 36C77026Q0061, aimed at supporting the Consolidated Mail Outpatient Pharmacy (CMOP) in fulfilling its Open Market (OM) purchasing needs. The RFI seeks to identify both small and large businesses capable of providing a range of pharmaceutical products and ancillary items, with a focus on those manufactured in the United States, to enhance the supply chain for approximately 450,000 prescriptions mailed daily to Veterans. Interested manufacturers are required to submit detailed company and product information, including FDA-approved NDC numbers and operational capabilities, by March 15, 2026, at 4:30 PM CT. For further inquiries, respondents can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    DA01--New Contract - Polypharmacy (VA-26-00018584)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for a new contract titled "Reducing Inappropriate Polypharmacy" to address medication management issues within the VA healthcare system. The procurement aims to develop and implement software solutions that will enhance program management, pilot phases, and sustainment of services, with an estimated total award amount of $47 million over a base period of six months and four one-year option periods. This initiative is critical for improving patient care and reducing the risks associated with polypharmacy among veterans. Interested parties must respond to the solicitation by January 14, 2026, at 10 AM Eastern Time, and can contact Contract Specialist Elena Juliano at elena.juliano@va.gov or 848-377-5194 for further information.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    DA01--Reducing Inappropriate Polypharmacy at the Department of Veterans Affairs
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking proposals for a software solution aimed at reducing inappropriate polypharmacy among Veterans, as outlined in the presolicitation notice for Request for Information (RFI) number 36C10B25Q0550. The objective is to identify multi-drug interactions, optimize medication regimens, and support deprescribing through sophisticated, clinically-evidenced technology that adheres to VA's IT standards and ensures secure handling of patient data. This initiative is critical for improving medication management and clinical outcomes for Veterans, with a formal Request for Proposal (RFP) to be issued via Contracting Opportunities. Interested parties must ensure full registration in the System for Award Management (SAM.gov) and submit their responses by September 15, 2025, at 3 PM Eastern Time. For inquiries, contact Contract Specialist Elena Juliano at elena.juliano@va.gov or Contracting Officer John Vardouniotis at ioannis.vardouniotis@va.gov.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--RX - PYLARIFY (PIFLUFOLASTAT F 18 INJECTION) (NDC 71258-0022-01)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking sources for the procurement of Pylarify (Piflufolastat F 18 Injection), a radiopharmaceutical injection, to be delivered to VISN 2 Downstate Hospitals. This Sources Sought Notice aims to identify potential large and small businesses, including manufacturers and distributors, capable of providing functionally equivalent products. The procurement is essential for the VA's medical supply needs, particularly in the context of radiopharmaceutical applications in patient care. Interested parties must submit their responses, including firm details and contact information, via email to Aleta Jennette at Aleta.Jennette@va.gov by January 12, 2026, at 10 AM Eastern Time.
    6505--Buprenorphine Pre-solicitation notice
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking suppliers for Buprenorphine HCL/Naloxone HCL Sublingual Tablets, as outlined in the pre-solicitation notice VA797E26R0004. The procurement aims to establish a reliable supply source for federal healthcare programs, including the VA, DoD, IHS, and BOP, with a contract consisting of a one-year base period and four one-year option periods. These medications are critical for treating opioid dependence, and offerors must provide pricing for specific tablet strengths, comply with FDA manufacturing standards, and submit a Letter of Commitment from the manufacturer. Interested parties should contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further details, as compliance with various regulatory requirements and timely submission of quarterly sales reports will be essential for successful participation in this opportunity.
    6515--MSPV BPA Solicitation
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified suppliers to establish Blanket Purchase Agreements (BPAs) for Medical/Surgical Prime Vendor (MSPV) supplies, specifically consumable medical and surgical items, for nationwide use within the Veterans Health Administration (VHA). This procurement aims to ensure the availability, consistency, and standardized pricing of medical supplies while adhering to compliance regulations, including the Federal Acquisition Regulation (FAR) and the Trade Agreements Act. The solicitation is set aside for Service-Disabled Veteran-Owned Small Businesses (SDVOSBC) and emphasizes the importance of authorized distributors, competitive pricing, and adherence to electronic data interchange (EDI) standards. Interested parties must submit their quotes by January 19, 2026, and can direct inquiries to Contracting Officer Katherine (Katie) Corcoran at katherine.corcoran@va.gov or 401-402-4678.